Feasibility of a Virtually Delivered LASO-3 Diet Intervention for Chemotherapy-Induced Peripheral Neuropathy in Post-Treatment Cancer Survivors

What this Trial Is About

This clinical trial investigates whether a virtually delivered diet intervention called LASO-3 can help improve chemotherapy-induced peripheral neuropathy CIPN in cancer survivors after treatment. CIPN is nerve damage caused by chemotherapy that leads to numbness, tingling, or pain in the hands or feet, and currently, there are few treatments available. The LASO-3 diet focuses on reducing added sugar intake, increasing fiber, and boosting omega-3 fatty acids to reduce inflammation, which may contribute to CIPN. Participants are randomly assigned to one of two groups. One group receives virtual LASO-3 nutrition counseling sessions led by a Registered Dietitian over 12 weeks, starting with weekly 30-minute sessions for 4 weeks, followed by biweekly 15-minute sessions for 8 weeks. The other group attends eight virtual general health education sessions lasting 15 to 30 minutes over 12 weeks, and may receive intervention materials and up to four dietary counseling sessions after the study. Blood samples are collected from all participants throughout the trial. Participants complete patient-reported outcome measures at the start and after 12 weeks. Researchers track recruitment, session attendance, and self-reported adherence to the diet goals, as well as acceptability and satisfaction with the intervention. The trial lasts up to 24 weeks and involves regular virtual sessions, blood collections, and surveys to assess the impact of the diet on CIPN symptoms in post-treatment cancer survivors.

A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment